# Exhaled breath drug detection using differential mobility spectrometry

> **NIH NIH R42** · VOX BIOMEDICAL LLC · 2020 · $59,276

## Abstract

Project Summary
This proposal seeks to expand upon breath analysis technology that is being actively studied as the focus of NIH
grant #6R42DA049655-02 and leverage this technology for rapid COVID-19 diagnostics. There is a dire need
for sensitive and specific diagnostic tests for COVID-19 that can be performed quickly. The differential mobility
spectrometry (DMS) breath analysis technology currently under investigation for drug detection may be adapted
to fill this void.
During this supplement we will perform a biomarker discovery effort to determine the exhaled breath molecular
species most suitable for use as a COVID-19 biomarker. Once a target species has been identified, methods of
capture that can be implemented within the safety paradigm governing COVID-19 testing will be investigated.
We will also initiate conversation with the FDA and develop an FDA approval strategy to expedite the deployment
of a future breath based COVID-19 diagnostic instrument based upon the technology being studied under this
administrative supplement’s parent grant.

## Key facts

- **NIH application ID:** 10193627
- **Project number:** 3R42DA049655-02S1
- **Recipient organization:** VOX BIOMEDICAL LLC
- **Principal Investigator:** Jacob Golde
- **Activity code:** R42 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $59,276
- **Award type:** 3
- **Project period:** 2020-07-01 → 2021-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10193627

## Citation

> US National Institutes of Health, RePORTER application 10193627, Exhaled breath drug detection using differential mobility spectrometry (3R42DA049655-02S1). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10193627. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*